Analysts expect Perrigo Co.’s voluntary recall of a key asthma drug to provide an opportunity for Lupin Ltd. and Cipla Ltd.—the two Indian pharmaceutical companies that received the U.S. health regulator’s approval for the product this year amid the novel coronavirus outbreak.
The Dublin-based company announced a voluntary recall of albuterol sulphate inhalation aerosol—developed in partnership with and manufactured by Catalent Pharma Solutions—in the U.S., according to a statement on its website. These actions, the company said, were being taken out of an abundance of caution as a result of complaints that some units may not dispense due to clogging.
This setback for Perrigo comes as an unexpected positive for Lupin and Cipla—the rivals in the $850-900 million U.S. albuterol sulfate market, according to Macquire.
“Currently, we are building $40 million sales for Lupin and…
